These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 80268)

  • 1. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W; Woodcock TM; Gordon CS; Krakoff IH
    Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
    Presant CA; Vietti T; Valeriote F
    Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
    Klubes P; Cerna I
    Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
    Presant CA; Coulter D; Valeriote F; Vietti TJ
    J Natl Cancer Inst; 1981 Jun; 66(6):1151-4. PubMed ID: 6165854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of tetrahydrouridine in experimental animals.
    el-Dareer SM; White V; Chen FP; Mellett LB; Hill DL
    Cancer Treat Rep; 1976 Nov; 60(11):1627-31. PubMed ID: 828522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
    Presant CA; Vietti TJ; Valeriote F; Coulter DM
    J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
    Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
    Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Perez LM; Greer S
    Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion.
    Israili ZH; Vogler WR; Mingioli ES; Pirkle JL; Smithwick RW; Goldstein JH
    Cancer Res; 1976 Apr; 36(4):1453-61. PubMed ID: 57000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.